The effects of short term intravenous administration of gallopamil on coronary haemodynamic variables were studied in 10 patients with stable exertional angina and angiographically confirmed coronary artery disease that affected the proximal portion of the left anterior descending artery. Blood flow in the great cardiac vein was measured by a thermodilution technique, both at rest and during ischaemia induced by atrial pacing, before and after intravenous administration of gallopamil (0-02 mg/kg as a bolus dose given over three minutes, followed by an infusion of 0 0005 mg/kg/min). Gallopamil significantly prolonged the mean (SD) duration of pacing that was tolerated (11 (2-6) vs 14 8 (2-4)) min, significantly increased the mean (SD) peak heart rate attained during pacing (142 (15) vs 158(11) beats/min), and reduced mean (SD) arterial pressure (133 (17) vs 116 (17) mm Hg). There were no changes in mean (SD) blood flow in the great cardiac vein (134 1 (57) vs 112-9 (38) ml/min, mean (SD) anterior regional coronary resistance (1 18 (0 6) vs 1 15 (0-5) mm Hg/ml/min), and mean (SD) anterior regional myocardial oxygen consumption (16 6 (6) vs 13-7 (4) ml/min).
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These data confirm that gallopamil is an effective antianginal agent and suggest that a reduction of myocardial oxygen demand is the predominant mechanism by which the drug exerts its beneficial effects.
The antianginal efficacy of calcium channel blocking agents such as verapamil,'l nifedipine,46 and diltiazem79 is well established. The mechanism of the effect depends on the affinity of the agent for its receptor sites and the cause of ischaemia, and is achieved by a reduction in myocardial oxygen consumption by an improvement in oxygen supply or both. 12 There is evidence that gallopamil exerts its antianginal effect by improving the ratio of myocardial oxygen supply to oxygen demand. But the mechanism of this action has not been elucidated.
We studied 10 patients with stable exertional angina and angiographically confirmed disease of the proximal portion of the left anterior descending coronary artery. Thermodilution measurements of blood flow in the great cardiac vein-that is the venous efflux from the territory supplied by the left anterior descending artery 3-were taken at rest and during myocardial ischaemia induced by rapid atrial pacing both before and after the short term intravenous administration of gallopamil. The effects of the drug on pacing tolerance were then related to Coronary haemodynamic effects of gallopamil coronary haemodynamic changes in the anterior region of the heart in which perfusion was jeopardised.
Patients and methods

PATIENTS
We studied 10 54 (4) 16 (5) 72 (9) LVEDP, left ventricular end diastolic pressure; EF, ejection fraction; LAD, left anterior descending coronary artery; Cfx, circumflex;
RCA, right coronary artery.
group.bmj.com on April 5, 2017 -Published by http://heart.bmj.com/ Downloaded from De Servi, Ferrario, Ghio, Mussini, Angoli, Bramucci, Bartoli, Poma, Rondanelli, Specchia No difference was observed at rest whereas heart rate increased and mean arterial pressure decreased at peak pacing after gallopamil had been given. As a result the double product remained unchanged; however, pacing was tolerated for longer after gallopamil. (TABLE 3) The end points of the coronary sinus pacing were angina in seven patients and ST segment depression of >2mm without pain in the remaining three. After gallopamil only four patients complained of angina, five patients showed asymptomatic ST segment depression of >2 mm, and in one (case 6) pacing was stopped after the maximal pacing rate had been maintained for two minutes. In all but one patient (case 8) end points were reached at higher pacing rate after gallopamil (control 142(15), gallopamil 158(11) beats/min, p < 0 001). As a result gallopamil increased mean pacing time from 11-0(2-6) to 14-8(2-4) minutes (p < 0001) while maximal ST segment depression decreased from 1-9 (0 5) to 1-6 (0-7) mm (p = NS).
HAEMODYNAMIC AND METABOLIC EFFECTS OF GALLOPAMIL AT PEAK PACING
As mean arterial pressure decreased from 133 (17) to 116 (17) mm Hg (p < 0 005) the peak pacing double product was slightly but not significantly reduced (fig 1) . There was no significant change in great cardiac vein flow or in anterior regional coronary resistance (fig 2) . Anterior regional myocardial oxygen consumption was also unchanged after gallopamil (from 16-1 (6) to 13-7 (4) ml/min, p = NS).
The mean plasma concentration of gallopamil at peak pacing was 41-4 (13-8) ng/ml.
Discussion
Gallopamil is a new calcium antagonist with the structure of a phenylalkilamine derivative, like verarior descending artery only, three had double vessel, and three had triple vessel disease (table 1). The mean ejection fraction was 0-72 (0-09) and the mean left ventricular end diastolic pressure was 16(5) mmHg.
HAEMODYNAMIC AND METABOLIC EFFECTS
OF GALLOPAMIL AT REST (TABLE 2) The heart rate was unchanged after administration of the drug (77 (19) vs 78 (14) beats/min, p = NS). Mean arterial pressure fell in all but one patient (case no 8); however, the difference did not reach statistical significance (117 (15) The mechanism by which this drug exerts its beneficial effects has yet to be established. After long term oral administration Khurmi et al found that the rate-pressure product at peak exercise was higher than after placebo.'0 Because the degree of ST segment depression was unchanged these workers suggested that the greater exercise capacity induced by gallopamil was the result of improved myocardial oxygen supply. By contrast, Rettig and Sen found that the double product did not increase at the end of exercise, either after short term or after long term oral administration.'2 Similarly, Scrutinio et al reported that the rate-pressure product was not modified at maximal workload"; this suggests that the drug may improve exercise capacity by reducing oxygen demand.
In our study short term intravenous administration of gallopamil improved pacing tolerance, confirming the antianginal activity of the drug. Because all patients had a proximal lesion of the left anterior descending artery we measured blood flow in the great cardiac vein, which is a reliable index of blood flow through that artery,'3 15 16 to assess haemodynamic changes in the area of the myocardium in which perfusion was jeopardised. Gallopamil did not increase blood flow in the great cardiac vein either at rest or at peak atrial pacing. Thus the beneficial effect of the drug does not seem to be related to increased perfusion of ischaemic regions. Moreover, myocardial oxygen consumption in the anterior region was similar at the peaks of the two pacing periods despite the higher heart rate that was achieved after gallopamil infusion. This suggests that the mechanism of action of the drug was a reduction in myocardial metabolic demand. Because most of our patients had multivessel disease, however, we cannot exclude the possibility that gallopamil increased blood flow to the non-anterior, yet potentially ischaemic myocardium and that such increase contributed to the improved performance induced by the drug. This possibility, however, seems remote, because the double product, a reflection of the maximal rate at which the obstructed coronary arteries deliver oxygen, was unchanged at peak pacing after gallopamil.
In conclusion, our data confirm that gallopamil is an effective antianginal drug that may well prove to be a useful addition to current treatment of angina pectoris. A reduction of myocardial oxygen consumption seems to be the predominant mechanism by which the drug exerts its beneficial effects.
